Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 5von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Hemangioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

Surveys and Questionnaires 6Methods 6Radiotherapy 5Cisplatin 5pembrolizumab 4durvalumab 3Sentinel Lymph Node Biopsy 3Radiosurgery 3Palliative Care 3Indocyanine Green 3Early Intervention, Educational 3Brachytherapy 3Bleomycin 3tremelimumab 2aldesleukin 2Surgical Procedures, Operative 2Radiation 2Paclitaxel 2Interviews as Topic 2Immunoglobulin G 2Imiquimod 2Gemcitabine 2Electrochemotherapy 2Drug Therapy 2Disulfides 2Dehydroepiandrosterone 2Counseling 2Carboplatin 2Biopsy 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vulvar Neoplasms × belzutifan × Clear all
NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡